Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)
Yungan Tao(Université Paris-Saclay), Jean Bourhis(University of Lausanne), X. Liem(Centre Oscar Lambret), N. Colin-Barailhou(Groupe d'Oncologie Radiothérapie Tête et Cou), C. Lafond(Centre Jean Bernard), Clément Sire(Centre National de la Recherche Scientifique), J. Miroir(Centre Jean Perrin), Juliette Thariat(Centre National de la Recherche Scientifique), Laurent Martin(Groupe Hospitalier du Havre), X.S. Sun(L'Hôpital Nord Franche-Comté), Aline Maillard(Institut Gustave Roussy), Cécile Michel(Groupe d'Oncologie Radiothérapie Tête et Cou), A. Aupérin(Inserm), Alexandre Coutté, F. Rolland(Institut de Cancérologie de l'Ouest), J. Guigay(Centre Antoine Lacassagne)
Cited by 6
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806